Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia
Ault, Kevin A
Garland, Suzanne M
Ferris, Daron G.
Koutsky, Laura A
Sings, Heather L
Haupt, Richard M
MetadataShow full item record
AbstractObjectives: High-risk human papillomavirus (hrHPV) is the primary cause of cervical cancer. As Chlamydia trachomatis is also linked to cervical cancer, its role as a potential co-factor in the development of cervical intraepithelial neoplasia (CIN) grade 2 or higher was examined.
Methods: The placebo arms of two large, multinational, clinical trials of an HPV6/11/16/18 vaccine were combined. A total of 8441 healthy women aged 15â 26â years underwent cervicovaginal cytology (Papanicolaou (Pap) testing) sampling and C trachomatis testing at day 1 and every 12 months thereafter for up to 4 years. Protocol-specified guidelines were used to triage participants with Pap abnormalities to colposcopy and definitive therapy. The main outcome measured was CIN.
Results: At baseline, 2629 (31.1%) tested positive for hrHPV DNA and 354 (4.2%) tested positive for C trachomatis. Among those with HPV16/18 infection (n=965; 11.4%) or without HPV16/18 infection (n=7382, 87.5%), the hazard ratios (HRs) associated with development of any CIN grade 2 according to baseline C trachomatis status were 1.82 (95% CI: 1.06 to 3.14) and 1.74 (95% CI 1.05 to 2.90), respectively. The results were comparable when only the 12 most common hrHPV infections were considered, but the excess risk disappeared when the outcome was expanded to include CIN grade 3 or worse.
Conclusion: Further studies based on larger cohorts with longitudinal follow-up in relation to the C trachomatis acquisition and a thorough evaluation of temporal relationships of infections with hrHPV types, C trachomatis and cervical neoplasia are needed to demonstrate whether and how in some situations C trachomatis sets the stage for cervical carcinogenesis.
Trial registration: NCT00092521 and NCT00092534.
CitationSex Transm Infect. 2011 Aug 6; 87(5):372-376
- Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.
- Authors: Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ
- Issue date: 2006 Jul
- Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines.
- Authors: Bais AG, Rebolj M, Snijders PJ, de Schipper FA, van der Meulen DA, Verheijen RH, Voorhorst F, van Ballegooijen M, Meijer CJ, Helmerhorst TJ
- Issue date: 2005 Aug 10
- Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3.
- Authors: Zhao C, Amin M, Weng B, Chen X, Kanbour-Shakir A, Austin RM
- Issue date: 2013 Jul
- Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
- Authors: Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, Lloveras B, Alejo M, Català I, Alameda F, Casas M, Bosch FX, de Sanjosé S
- Issue date: 2012 Jan 26
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
- Authors: Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ
- Issue date: 2012 Jan